You can buy or sell Zymeworks and other stocks, options, ETFs, and crypto commission-free!
Zymeworks Inc., also called Zymeworks, is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. Read More The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani, and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.
Vancouver, British Columbia
52 Week High
52 Week Low
Simply Wall StMar 8
Do Directors Own Zymeworks Inc. (TSE:ZYME) Shares?
Every investor in Zymeworks Inc. (TSE:ZYME) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. Companies that have been privatized tend to have low insider ownership. Zymeworks is a smaller company with a market capitalization of CA$690m, so it may still be flying under the radar of many institutional investors. Our analysis of the ownership of the company, below, shows that...
Stock Price, News, & Analysis for Zymeworks
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd....
Expected Apr 30, After Hours